A multicenter, parallel-arm, placebo-controlled, double-blind study to evaluate the efficacy and safety of tadalafil administered once daily to men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

Trial Profile

A multicenter, parallel-arm, placebo-controlled, double-blind study to evaluate the efficacy and safety of tadalafil administered once daily to men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2007

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Acronyms PILUTS
  • Sponsors Eli Lilly; ICOS Corporation; Lilly ICOS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top